Validated Critical Roles of Bruton’s Tyrosine Kinase (BTK) in Chronic Lymphocytic Leukemia (CLL)

A Journal of Postdoctoral Research.

JobsArticleAuthors

ISSN : 2328-9791

Validated Critical Roles of Bruton’s Tyrosine Kinase (BTK) in Chronic Lymphocytic Leukemi

Yiming Zhong and Yuh-Ying Yeh

The Ohio State University

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

zhong.32@osu.edu

Chronic lymphocytic leukemia (CLL) is a type of blood cancer with accumulated abnormal B cells growing out of control in bone marrow, blood and secondary lymphoid organs. It is the most common adult leukemia in the western world and remains incurable. Identification of therapeutic targets and development of effective target therapies are crucial and highly demanding. The well tolerated Bruton's tyrosine Kinase (BTK) inhibitor, ibrutinib (formally called PCI-32765), represents one of the most exciting breakthroughs in the field of B cell malignancy therapy. In clinical investigation ibrutinib has been shown to have significant clinical activity against B cell malignancies including CLL and it was recently approved for the treatment of mantle cell lymphoma and CLL. BTK is a critical component of the B cell receptor (BCR) signaling pathway...